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Abstract
Vinpocetine (VPN) is a synthetic ethyl-ester derivative of the alkaloid 
 apovincamine from Vinca minor leaves. VPN is a selective inhibitor of phospho-
diesterase type 1 (PDE1) has potential neurological effects through inhibition 
of voltage gated sodium channel and reduction of neuronal calcium influx. VPN 
have noteworthy antioxidant, anti-inflammatory and anti-apoptotic effects with 
inhibitory effect on glial and astrocyte cells during and following ischemic stroke 
(IS). VPN is effective as an adjuvant therapy in the management of epilepsy; 
it reduces seizure frequency by 50% in a dose of 2 mg/kg/day. VPN improves 
psychomotor performances through modulation of brain monoamine pathway 
mainly on dopamine and serotonin, which play an integral role in attenuation 
of depressive symptoms. VPN recover cognitive functions and spatial memory 
through inhibition of hippocampal and cortical PDE-1with augmentation of 
cAMP/cGMP ratio, enhancement of cholinergic neurotransmission and inhibi-
tion of neuronal inflammatory mediators. Therefore, VPN is an effective agent in 
the management of ischemic stroke and plays an integral role in the prevention 
and attenuation of post-stroke epilepsy, depression and cognitive deficit through 
direct cAMP/cGMP-dependent pathway or indirectly through anti-inflammatory 
and anti-oxidant effects.
Keywords: vinpocetine, phosphodiesterase type 1, antioxidant, anti-inflammatory, 
stroke, post-stroke
1. Introduction
Vinpocetine (VPN) is a synthetic ethyl-ester derivative of the alkaloid apovin-
camine from Vinca minor leaves which is known as lesser periwinkle. A VPN has a 
specific chemical structure contains carboxylic acid ethyl ester which is soluble in 
alcohol, acetone and sulfoxide, Figure 1 [1].
VPN is widely used in the treatment of different cerebro-vascular disorders, 
cognitive dysfunction, memory disorders, tinnitus, macular degeneration and 
glaucoma. In addition, VPN is effective in the management of acute kidney injury, 
renal stone, hair loss and peptic ulceration [2].
Nevertheless, this critical review only focused on the potential role of VPN in 
the management of ischemic stroke.
A multiplicity of search strategies was taken and assumed which included 
electronic database searches of Medline and Pubmed using MeSH terms, keywords 
and title words during the search. The terms used for these searches were as fol-
lows: [Vinpocetine OR apovincamine] AND [cognitive function OR stroke OR 
brain ischemia OR blood flow OR cerebral circulation OR oxidative stress OR blood 
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viscosity OR cerebral blood flow]. [Vinpocetine OR apovincamine] AND [cerebral 
metabolism OR cerebral hypoxia OR ischemic degeneration OR minor stroke]. 
Reference lists of identified and notorious articles were reviewed. In addition, only 
English articles were considered and case reports were not concerned in the review. 
The key features of recognized applicable search studies were considered and the 
conclusions summarized in a critical review.
2. Pharmacology of vinpocetine
VPN is a selective inhibitor of phosphodiesterase type 1 (PDE1) which increas-
ing of cAMP and cGMP leading to vasodilatation. Also, it inhibits the release of 
pro-inflammatory cytokines through inhibition of IKK/NF-kB activator protein-1 
(AP-1) pathway which is involved in the propagation of inflammatory cytokines 
translocation and release [3]. Moreover, VPN has potential neurological effects 
through inhibition of voltage gated sodium channel, reduction of neuronal calcium 
influx and antioxidant effect with augmentation of dopamine metabolism since 
it increases 3, 4-dihydroxyphenylacetic acid (DOPAC) which is the breakdown 
metabolites of dopamine [4].
It has been reported that VPN is a safe drug for long-term use and it well toler-
ated during the management of cerebrovascular disorders. Mild side effects such 
as headache, flushing, anxiety, dry mouth and nausea have been accounted during 
VPN uses. In spite of potent non-selective vasodilator effect it does not produce 
stealing effect on cerebral vasculatures due to the viscosity lowering effect and 
inhibition of platelet aggregations which together improve cerebral vessels rheologi-
cal properties. Nevertheless, VPN does not reduce blood pressure and systemic 
circulation during acute and chronic uses [5].
VPN is well absorbed from small intestine, which increased by food, therefore, 
fasting bioavailability is 6.7% and non-fasting bioavailability is 60–100%. Similarly, 
VPN has no significant drug-drug interactions with different drugs such as oxaze-
pam, imipramine, glibenclamide and other agents that are used in the management 
of ischemic stroke [6].
3. Vinpocetine in ischemic stroke
Ischemic stroke (IS) represents the main leading cause of death in the American 
Unite State and developed countries and regarded it as the main cause of long-term 
disability. IS represents 11.9% of annual total death and accounts for 90% of all 
Figure 1. 
Chemical structure of Vinpocetine.
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stroke cases [7]. Arboix study discussed briefly the risk factor of IS [8]. These risk 
factors are divided into non-modifiable risk factors (sex, age, inherited factors, ethi-
cinity and low birth weight at birth) and modifiable risk factors (diabetes mellitus, 
hypertension, smoking, obesity, alcohol abuse, oral contraceptive and metabolic 
syndrome). [9] IS is mainly caused by arterial thrombosis on the atherosclerotic 
plaque of cerebral vessels, causing cerebral ischemia, infarction and induction of 
peri-infarct inflammation. Neuro-inflammations contribute into tissue repair and 
neuronal damage as well as retrograde and anterograde axonal degenerations [10]. 
IS leads to glucose and oxygen deprivation of neuronal cells which causing oxidative 
stress, excitotoxicity and calcium overload which eventually causing neuronal cell 
death and development of infarction core [11]. The infracted core and damaged neu-
ronal cells due to induced oxidative stress, releasing of various inflammatory mole-
cules that causing vasculitis and damage of blood brain barrier (BBB) [12]. Moreover, 
activated microglia and infiltrated macrophage during IS release neurotransmitters 
which are interact with neurons causing neuroinflammation and neuronal injury. 
As well, interleukin-8(IL-8), NF-kB and tumor necrosis factor (TNF-α) are over-
expressed during IS which play a potential role in the initiation of inflammation and 
apoptosis [13]. In a similar way, vascular smooth muscle and endothelial cells of cere-
bral vasculature are activated by NF-kB pathway leading to further obstruction and 
thrombosis. Therefore, NF-kB pathway is an important pathway in the pathogeneses 
and development of neurological deficit thus; inhibition of NF-kB pathway by VPN 
is regarded as important and main mechanism of VPN neuroprotection [14].
In addition, activated microglia expresses cholesterol transporter protein (TSPO) 
which is over-expressed during brain injury and IS and inhibited by VPN [15].
During IS voltage gated sodium channels are activated causing intracellular 
accumulation of Na and Ca leading to neuronal cell damage, excitotoxicity, edema, 
acidosis and acute cellular dysfunctions. VPN inhibits voltage gated sodium chan-
nels leading to dose dependent reduction of intracellular concentrations of Na 
and Ca. Thus, the neuroprotective effect of VPN during IS is chiefly mediated by 
inhibition of neuronal voltage gated sensitive Na-channel [16].
Different studies illustrated that oxidative stress, excitotoxicity and impaired 
energy metabolism leading to neuronal death by both apoptosis and necrosis 
during IS. These events lead to reduction of cAMP system which is important in 
the expression and regulation of brain derived neurotrophic factor (BDNF), which 
improves neuronal survival. PDE1 is mainly localized in striatum and cortex which 
participating in the regulation of neuronal motor activity [17, 18].
Indeed, VPN increases neuronal cGMP through inhibition of calmodulin 
dependent phosphodiesterase which improves cerebral blood flow and oxygen con-
sumption [19]. VPN improves cerebral metabolism through enhancing glucose and 
oxygen supply and ATP production by cerebral vasodilation. These effects prevent 
IS induced-memory and cognitive dysfunctions due to improvement of neurotrans-
mitters such as serotonin, dopamine and noradrenaline, which are involved in the 
regulation of cognitive function [20].
3.1 Antioxidant effects of vinpocetine in ischemic stroke
In IS overproduction of free radicals and reactive oxygen and/or nitrogen spe-
cies lead to neuro-pathological changes through complex interactions with cellular 
components such as proteins, DNA and lipids. Free radicals, mainly superoxide 
and non-radicals such as hydrogen peroxide may cause further neurological injury 
through depletion of endogenous antioxidant capacity. Therefore, drug with anti-
oxidant potential may play a role in the prevention of cerebral injury during IS [21].
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Recent study by Al-Kuraishy et al. reported that VPN is a potent antioxidant 
agent which improves antioxidant capacity and reduces of oxidative stress [22]. 
As well, Santos et al., study illustrated that VPN attenuates oxidative stress during 
IS through inhibition of lipid peroxidation and generation of free radical [23]. In 
addition, VPN has a potential neuroprotective effect, though antioxidant effect 
since it prevents oxidative stress injury and toxic demyelination in rat brain [24]. 
The antioxidant neuroprotective effect of VPN is mainly at low-moderate doses 
since; high doses of VPN lead to oxidative stress due to prooxidant and proinflam-
matory effects [25]. Deshmukh et al. reported that antioxidant potential of VPN 
contributes into the prevention of IS induced-neuronal injury through modulation 
of cholinergic neurons [26]. Therefore, antioxidant mechanisms of VPN are related 
to direct free radical scavenging effect, potentiating of endogenous antioxidant 
capacity and inhibition the generation of free radicals. The molecular antioxidant 
effect of VPN is linked to the suppression of ADP stimulated respiration, mitochon-
drial Na+/Ca+ exchange, mitochondrial swelling and regulation of mitochondrial 
membrane potentials [16, 27].
3.2 Anti-inflammatory effects of vinpocetine in ischemic stroke
IS induced-inflammatory changes and neuroinflammations lead to secondary 
brain damage. Toll-like receptors (TLRs) are over-expressed in IS, leading to the 
induction the release of pro-inflammatory mediators through myeloid differentia-
tion factor-88 (MyD88) dependent pathway and Toll /IL-IR domain-containing 
adaptor factor protein inducing interferon-beta (TRIF) dependent pathway [28]. 
Therefore, inhibition of TLR4/MyD88 and NF-KB pathways lead to noteworthy 
neuroprotection against IS. It has been noted that VPN inhibits TNF-α induced 
NF-KB activation, pro-inflammatory releases and inflammatory biomarkers such as 
Figure 2. 
Anti-inflammator effects of vinpocetine. (A) Basic effect, (B) Anti-inflammatory effect.
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IL-1β and IL-33 in an experimental ischemic model [5]. In intriguing way, Zhang 
and Yang reported that VPN inhibits the release of chemokines and inflammatory 
cytokines from microglia, macrophage and endothelial cells in IS through inhibi-
tion of NF-KB pathways in IS and associated atherosclerosis [29]. In a similar way, 
VNP leads to the significant neuroprotective effect and regulation of neuronal 
plasticity through the anti-inflammatory effect which is mediated by suppression of 
IB-Kinase (IKK) pathway in IS, Figure 2 [30, 31].
Usually, microglia cells are resident macrophages in the brain and act as an 
active immune defense against cerebral injury and infection through induction and 
regulation of neuro-inflammatory reactions. Microglia improves brain homeostasis 
through removal of tissue debris, dead cells, and induction of neurogenesis and 
preservation of myelin sheath with secretion of neuroprotective factors such as 
insulin-like growth factor. On the other hand, activated microglia leads to neuronal 
injury during IS through the release of TNF-α, IL-6, IL1β and nitric oxide (NO) 
[32]. It has been reported that VPN inhibits neuronal inflammation in IS through 
suppression of microglia activity [33]. Also, VPN inhibits IS induced-inflammatory 
changes and reduces brain edema and infarction size mainly through inhibition the 
expression of NF-KB and TNF-α in the activated microglia which is PDE1 indepen-
dent pathway [34].
3.3 Effects of vinpocetine on ischemic reperfusion injury in ischemic stroke
Ischemic-reperfusion (I/R) injury in IS leads to activations of perivascular 
macrophages, which play a role in the progression of neuronal damage through 
the release of proinflammatory biomarkers which also participate in the injury 
to blood brain barrier. Furthermore, activate macrophages, microglia, T-cells 
and dendritic cells infiltrate the infarct site following I/R injury causing further 
damage through the release of monocyte chemoattracting protein (MCP-1) which 
attracts circulating neutrophils into the injury site. VPN inhibits TNF-α induced- 
IKKα/β activation with reduction of target genes activations and reduction of 
various forms of proinflammatory cytokines and mediator following I/R injury in 
IS, Figure 3 [35, 36].
In addition, injured neurons in IS release specific proteins called danger associ-
ated molecular patterns including; heat shock protein (HSP), high mobility group-
box 1 protein (HMGB-1), ATP and nicotinamide adenine dinucleotide (NAD) 
which activate TLR4 receptors on perivascular macrophage, microglia and endo-
thelial cells. Therefore, TLR4 antagonist reduces infarct size attenuates IS-induced 
inflammatory changes and I/R injury [37, 38]. Different in vitro and in vivo studies 
illustrated that VPN inhibits I/R injury in IS through suppression of TLR4 receptors 
and NF-KB signaling pathway in animal model studies [39].
Neuronal mitochondrial reactive oxygen species (ROS) contribute into the 
pathogenesis of I/R injury in IS as well as neurodegeneration and glutamate excitotox-
icity [40]. VPN activates peripheral benzodiazepine receptors (BBRs) which regulate 
mitochondrial outer cell membrane and prevent the opening of mitochondrial 
permeability transition pore (MPTP). Furthermore, VPN prevents mitochondrial 
dysfunction through the prevention of mitochondrial depolarization, inhibition of 
mitochondrial Na+/Ca2+ exchange, prevention of mitochondrial Ca+2 release, MPTP 
opening and the release of free radicals from outer mitochondrial membrane during 
neuronal injury [41]. Therefore, VPN regulates mitochondrial redox homeostasis 
through induction of ATP hydrolysis, inhibition of mitochondrial respiration and 
regulation of ATP synthesis. Thus, VPN preserves mitochondrial integrity and atten-
uates inflammatory and oxidative damage following I/R injury in IS. Moreover, Qiu 
et al., illustrated that VPN is effective in reducing the volume of cerebral infarct and 
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attenuation I/R injury through down-regulation of NF-KB p65 and cyclo-oxygenase 
2(COX-2) with up-regulation of peroxisome proliferator-activator receptor γ(PPARγ) 
which is neuroprotective mediator during IS [42].
3.4 Vinpocetine and post-ischemic stroke
3.4.1 Immunological and inflammatory reactions in post-ischemic stroke
In the brain, there is multiple communications between glial cell and other 
immune cells, which together participate in the immune reactions during ischemic 
events. In the post-ischemic stroke (PIS), B-cell, T-cell, macrophage and neutro-
phils enter the brain to connect and engage glial cells in immune interactions. This 
interaction maintains homeostasis and prevents further neuronal damage through 
generation of pro-survival factors like transforming growth factor-β and IL-10 
which promote the resolution of inflammations [43].
It has been noticed, that IS activates neuro-inflammations which increase the 
permeability of BBB leading to activation of mast cells and macrophages which 
release histamine and pro-inflammatory cytokines respectively which recruit 
immune cell to the site of injury leading to progression of ischemic injury [44].
Therefore, the relationship between immune cells and neurons during IS is so 
intricate relationship.
Microglia is regarded as a first line defense mechanism of innate immunity 
against ischemic injury which activated within hours following IS. There are two 
activation pathways for microglia, which are classical pathway (M1) and alternative 
pathway (M2). M1 activation leads to induction of inducible nitric oxide synthase 
Figure 3. 
Effects of vinpocetine on proiinflammatory mediators during ischemic-reperfusion (I/R) injury in ischemic 
stroke.
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(iNOS) and TNF-α causing neuronal damage while; M2 activation leads to induc-
tion the release of pro-inflammatory cytokines and arginase leading to neuro-
protection. [45] Aging is associated with impaired M2 activation and thus; M1 
activation overriding M2 causing more inflammatory changes in elderly patients 
with IS [46].
Similarly, astrocyte which is another type of glial cell contributes in the forma-
tion of BBB and activated following IS. Reactive astrocyte subdivided into A1plays 
a role in the neuronal damage through upregulation of complement genes, and A2 
plays a role in the neuroprotection through up-regulation of neurotrophic factors 
[47]. One month following PIS, astrocyte undergoes morphological and functional 
changes leading to reactive gliosis and activation of T-cell at ischemic regions [48].
Therefore, astrocyte and glial cells act as bridge interaction between neurons and 
immune system through different pro-inflammatory cytokines, Figure 4 [49]. It has 
been shown that inflammatory changes, glial and astrocyte activations at post-
stroke period participating together in the induction of different PIS complications 
such as depression, epilepsy, dementia and cognitive dysfunctions [50]. Vardian 
study illustrated that VPN have noteworthy antioxidant, anti-inflammatory and 
anti-apoptotic effects with inhibitory effect on glial and astrocyte cells during and 
following IS. Also, VPN reduces astrocyte edema and excitability through cAMP 
dependent-PKA pathway [51].
3.4.2 Vinpocetin for post-ischemic stroke epilepsy
Kim et al. reported that PIS predisposes for early and late onset epilepsy which 
called post-stroke seizure (PSS) due to the disturbances in the neuronal metabolic 
homeostasis, reactive gliosis, glutamate release and neuronal hyper-excitability 
[52]. Recently, Garza-Morales et al., found that VPN is effective as an adjuvant 
therapy in the management of epilepsy, it reduces seizure frequency by 50% in a 
dose of 2 mg/kg/day as compared with placebo [53]. The anti-epileptic mechanisms 
of VPN are through blockade of presynaptic Na-channels mediated glutamate 
release, inhibition of TNF-α and IL-1β which play a role in the augmentation of 
presynaptic Ca and Na permeability [54, 55].
Figure 4. 
Microglial and astrocyte activations in post-ischemic stroke. CCR2: chemokine receptor 2; PAMPs: pathogen-
associated molecular patterns; LPS: lipopolysaccharides; PD-1: programmed death-ligand 1; NK: natural 
killer; CD: cluster of differentiation.
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3.4.3 Vinpocetin for post-stroke depression
Post-stroke depression (PSD) is a critical psychiatric complication of IS character-
ized by psychomotor disturbances, fatigue and sleep disorders with a prevalence of 
33% following IS [56]. PSD is developed due to inflammatory reactions induced-
neuroplasticity and imbalance of pro-inflammatory/anti-inflammatory ratio which 
causing glutamate excitotoxicity and intracellular Ca dysregulation [57]. Different 
studies illustrated that inflammatory cytokines induced-PSD lead to a reduction in the 
synthesis of serotonin, brain derived neurotrophic factor and fibroblast growth fac-
tor-2 which are important in the regulation of mood and neurotransmission [58, 59].
Inflammatory cytokines are implicated in the induction of PSD through activa-
tion of indolamine-2,3-dioxygenase at the marginal zone of the infracted area 
leading to depletion of serotonin and initiation of depression [60]. Furthermore, 
Wierner et al. found that nerve growth factor (NGF) which important secretory 
protein inhibits apoptosis and improves neuronal differentiations was low in PSD 
[61]. On the other hand, calcitonin gene-related peptide (CGRP) which is a neuro-
protective peptide is elevated in patients with PSD and thus; CGRP antagonist could 
improve depressive symptoms [62].
Therefore, anti-inflammatory drugs with rehabilitation therapy enhance neu-
ronal plasticity and functional recovery after IS [63]. VPN reduces the inflamma-
tory processes and improves neuronal plasticity through inhibition the releases of 
inflammatory cytokines and chemokines from macrophage, microglia, and vascular 
smooth and endothelial cells with restoration of synaptic neurotransmissions [64]. 
As well, VPN improves psychomotor performances through modulation of brain 
monoamine pathway mainly on dopamine and serotonin, which play an integral role 
in attenuation of depressive symptoms [65]. Chen et al. reported that VPN improves 
neuronal functions and neurotransmission through modulation of NGF levels fol-
lowing IS [66]. Similarly, VPN improves neuronal transmission and inhibits induced 
pain pathway in PSD through down-regulation of CGRP [67]. Herewith, VPN 
attenuates PSD through different pathways either directly by activation of neuronal 
cAMP/cGMP pathway or indirectly through anti-oxidant, anti-inflammatory and 
modulation of brain peptides and neurotransmitters. Since, hippocampal cAMP-
PKA response element of BDNF signaling pathway is decreased in patients with 
PSD. So, improvement of neuronal cAMP could interestingly prevent PSD [68].
3.4.4 Vinpocetin for post-stroke cognitive deficit
Post-stroke cognitive deficit (PSCD) is defined as global cognitive disability 
within 6 months after stroke regardless of presumptive causes according to 
American Psychiatric Associations Diagnostic and Statistical Manual of Mental 
Disorder. As well, 30% of stroke survivor found to have a noteworthy degree of 
cognitive decline within the first month after the stroke [69]. It has been noticed 
that some cognitive disorders may also develop subsequent to transient ischemic 
attack (TIA) suggesting that PSCD used in this way does not propose underlying 
neuro-pathological changes. Therefore, PSCD seems to be suitable for dementia, 
which associated with vascular insult and neuro-degenerative processes [70]. 
Various cross-sectional and longitudinal studies illustrated a link between high lev-
els of inflammatory biomarkers in stroke survivors and risk of PSCD. Erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), IL-12 and IL-6 sera levels are 
elevated in patients with PSD and regarded as predictor factors [71, 72].
The inflammatory mechanism of PSCD is related to the dysregulation in inflam-
matory and immune factors since; reduction of IL-8 and IL-6 are associated with 
changes in both white and gray matters, suggesting a role in the pathogenesis of 
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PSCD. As well, IL-1, IL-10, TNF-α and α-synuclien are increased in PSCD [73]. 
Shen and Gao study reported that high somatostatin and low neuron specific 
enolase in patients with PSCD compared to the healthy controls [74].
Other mechanisms of PSCD are cerebral hypoperfusion, reduction in cerebro-
vascular reserve capacity, impairment of cerebral vasoreactivity and autoregulatory 
ability which together initiate abnormal neuronal cell membrane phosphorylation 
and amyloid beta formation [75]. In addition, irreversibly injured astrocytes are 
converted to clasmatodendrosis which leads to disruption of gliovascular associa-
tion at BBB in the white matter. Clasmatodendrosis is associated with cognitive 
disorders in patients with PSCD [76]. From these points, the mechanisms of PSCD 
remain obscure due to overlapping between neuro-pathological data and findings 
of PSCD and Alzheimer disease [77]. VPN improves cognitive functions and spatial 
memory through inhibition of hippocampal and cortical PDE-1with augmenta-
tion of cAMP/cGMP ratio, enhancement of cholinergic neurotransmission and 
inhibition of neuronal IKK/NF-kB [78, 79]. It has been noticed by Bitner study that 
both cAMP and cGMP activate PKA and cAMP-response element-binding protein 
(CREP) which improves synaptic plasticity and neurogenesis through up-regulation 
of BDNF. cAMP/cGMP/CREP pathway increases early and late long-term potentia-
tion of memory [80] Besides, other PDE inhibitors like sildenafil (PDE-5 inhibi-
tors) and cilostazol (PDE-3 inhibitor) also improve cognitive function and PSCD 
[81]. Recently, McQuown et al. illustrated that VPN improves memory function 
mainly through inhibition of PDE-1B isoform as it mainly located in regions with 
high dopaminergic neurotransmission such as the prefrontal cortex, striatum 
and dentate gyrus [78]. Therefore, VPN is an effective therapy in rehabilitation of 
cognitive, memory deficit and PSCD through modulation of inflammatory changes 
and enhancement of neuronal cAMP/cGMP in post-stroke survivors [82].
4. Conclusions
VPN is an effective agent in the management of ischemic stroke and plays an 
integral role in the prevention and attenuation of post-stroke epilepsy, depression 
and cognitive deficit through direct cAMP/cGMP-dependent pathway or indirectly 
through anti-inflammatory and anti-oxidant effects.
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